

Philip L. Penfold

Jan M. Provis

Editors

Macular Degeneration

Philip L. Penfold

Jan M. Provis

Editors

Macular Degeneration

With 70 Figures in 193 Separate Illustrations
and 14 Tables

Dr. Philip L. Penfold

Chief Scientist
Regenera Limited
PO Box 9
2 Brindabella Circuit
Canberra Airport
ACT 2609
Australia

Dr. Jan M. Provis

Research School of Biological Sciences
The Australian National University
GPO Box 475
Canberra
ACT 2601
Australia

Library of Congress Control Number: 2004105923

ISBN 3-540-20058-4 Springer Berlin Heidelberg New York

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

Springer is a part of Springer Science+Business Media

springeronline.com

© Springer-Verlag Berlin Heidelberg 2005

Printed in Germany

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: the publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Editor: Marion Philipp, Heidelberg, Germany
Desk Editor: Martina Hemberger, Heidelberg, Germany
Production: ProEdit GmbH, 69126 Heidelberg, Germany
Cover: E. Kirchner, Heidelberg, Germany
Typesetting: K. Detzner, 67346 Speyer, Germany

Printed on acid-free paper 24/3150 ML 5 4 3 2 1 0

Preface

This book provides a unique overview of current thinking on the pathogenesis, incidence and treatment of age-related macular degeneration (AMD). It includes, for the first time, a synthesis of the views of the world's leading scientists and clinical practitioners regarding retinal biology and the basic mechanisms, clinical and pathogenetic processes and rational approaches to the treatment of AMD.

Although the fovea is less than a millimetre in diameter, disorders of the fovea and its immediately surrounding area (the *macula*) are responsible for the majority of cases of untreatable blindness in the developed world. The basis for the vulnerability of the macula region in these degenerative changes is beginning to emerge. The fovea has a number of features that distinguish it from other parts of the retina and reflect its specialization for high visual acuity, principally a high density of photoreceptors and a lack of retinal vessels. Chapter 1, written by Anita Hendrickson, provides an overview of the anatomy of the primate macula. The fovea is a characteristic feature of the primate retina, lies on the temporal side of the optic disc and regards the central visual field. A sound understanding of macular anatomy is essential for understanding the impact of AMD on the patient.

In Chap. 2, we summarise the evidence suggesting a critical dependence of the central retina on vascular supply. The interrelationships between the physiological and immunological function of the blood-retinal barrier and the consequences of barrier breakdown are described. Increasing evidence is presented for the involvement of both resident microglia and choroidal leukocytes. New observations concerning the significance of drusen, the involvement of the retinal vasculature and the measurement of inflammation in AMD are presented for the first time. Taken together, the data lead to the conclusion that immunity plays both a primary and secondary role in the pathogenesis of AMD.

The link between photoreceptor dysfunction and the risk of neovascularization in Bruch's membrane is explored by Jackson and colleagues in Chap. 3. Because the RPE is polarized, problems pertaining to the re-supply of photoreceptors on the apical aspect of the RPE (leading to photoreceptor death) should be conceptually separated from problems pertaining to waste removal on the basal aspect of the RPE (leading to Bruch's membrane damage and neovascularization), at least for the purposes of designing mechanistic experiments. These processes are governed by different proteins and pathways at the cellular level and will be reflected in different risk factors and genetic predispositions at the population level. A rigorous test of a nutrient-deficiency hypothesis of AMD-associated photoreceptor death awaits more information about normal nutrient delivery mechanisms across the RPE/Bruch's membrane complex, intra-retinal contributions to photoreceptor nutrition,

changes in these mechanisms with age and pathology, and differential effects on rods and cones.

In Chap. 4, AMD is considered as a complex genetic disease in which environmental risk factors impact on a genetic background. Finding the genes that determine susceptibility or modify the disease process is one of today's challenges, but also offers a chance for understanding underlying disease processes and for the development of preventive strategies and treatments. This chapter explores our current knowledge about the genetic influences on AMD and indicates possible directions for future study.

Until recently, most of the information about the natural history of AMD has come from clinical and histopathological studies. Most such studies have previously been of short duration involving select groups of patients attending ophthalmology clinics or participating in trials in which severe disease may be overrepresented. In the past 15 years data from population-based studies have resulted in a better understanding of the epidemiology of this disease. Chapter 5 examines the epidemiology of AMD, focusing on data from several recent population-based studies.

In Chap. 6, the racial/ethnic differences in the incidence and prevalence of AMD in China are examined. In China AMD is considered one of the most important causes of blindness in those over the age of 50. With improvement of economic conditions in China, the most common causes of blindness such as cataract, corneal diseases, trachoma and glaucoma have been largely brought under control, while AMD has increased in prevalence, now fourth on the list of causes of blindness in the age group of those 60 years and over. Considering the large population of China, it has been estimated that AMD currently affects at least 20 million individuals.

Experimental models of age-related macular degeneration capture only selected features of the human disease. Animal models that encompass both atrophic and exudative aspects of retinal degenerations are needed to better understand disease progression and to predict and assess potential therapeutic approaches. Recent insights into the pathogenesis of macular degeneration, along with the combination of rapid screening techniques with transgenic and other methods, are giving rise to several promising experimental systems outlined by Ray Gariano in Chap. 7.

Normal function is dependent upon a balance between the generation of free radicals and oxidative species and the availability of antioxidants and free radical scavengers. David Pow and colleagues investigate the role of transporters and oxidative stress in AMD in Chap. 8. In Chap. 9, Jonathan Stone and colleagues describe a widespread degenerative phenomena observed at the edge of the 'normal' retina. The observations suggest that the edge of the retina is subject to localized stress throughout life, inducing a progressive degenerative process. These edge-specific changes are part of the life history of the normal retina and form part of the baseline against which retinal degeneration takes place.

In the final chapter Scott Cousins and colleagues address – in the context of the scientific information described in the other sections – current clinical research strategies to provide a concept-based overview of the status of current and future treatments for AMD. A brief review of key scientific definitions and pathogenic theories is followed by the rationale for current treatments and ongoing trials. Space is also set aside for a bit of “educated speculation” about the potential future directions of clinical research based upon scientific discoveries described in other chapters.

Acknowledgments

We are indebted to the contributing authors and many other colleagues for their help in preparing this book. Special thanks are due to Emily Bell for her assistance in formatting the initial submissions and to Diana van Driel, both for her contributions as an author and fellow electron microscopist and for her diligence as proof-reader *par excellence*.

Philip L. Penfold, MPhil., PhD.

Jan M. Provis, PhD.

Australian National University
Canberra, Australia

September 2004

Contents

1	Organization of the Adult Primate Fovea	1
	Anita Hendrickson	
1.1	Anatomy of the Human Fovea	1
1.1.1	General Anatomy	1
1.1.2	Photoreceptor Distribution, Types, and Numbers in the Human Retina	3
1.1.3	Inner Retinal Neurons Associated with Cones in Central Primate Retina	9
1.1.4	Vascular and Glial Specializations of the Fovea	12
1.1.5	Pigment Epithelium Numerical Relationships with Foveal Photoreceptors	13
1.2	Anatomy of the Old and New World Monkey Fovea: What Are the Differences with Human Foveas?	14
1.3	What Are the Anatomical Requirements to Create a Fovea?	17
1.3.1	Midget Ganglion Cells	17
1.3.2	High Cone Density and Types of Foveal Cones	18
1.3.3	Absence of Rods	18
1.3.4	Striate Cortex Expansion	19
1.3.5	Vascular Specializations	19
	References	20
2	Immunology and Age-Related Macular Degeneration	25
	Philip L. Penfold, James Wong, Diana van Driel, Jan M. Provis, Michele C. Madigan	
2.1	Introduction: Why the Macula?	25
2.2	The Immune Status of the Retina	26
2.2.1	The Blood-Retinal Barrier	26
2.2.2	Microglia	29
2.3	Immune Mechanisms in AMD	30
2.3.1	Blood-Retinal Barrier Breakdown	30

2.3.2	Pigmentary Disturbance	30
2.3.3	Drusen	31
2.3.4	Cell-Mediated Immunity and Inflammation	33
2.3.5	Humoral Immunity	35
2.4	Clinical Significance of Drusen	37
2.5	Atrophic (“Dry”) Macular Degeneration	37
2.6	Neovascular (“Wet”) Macular Degeneration	37
2.7	Involvement of the Retinal Vasculature in AMD	38
2.8	Leucocyte Common Antigen (CD45) Expression in AMD: A Measure of Inflammation	40
2.9	Conclusion	41
	References	41

3 Photoreceptor Degeneration in Aging and Age-Related Maculopathy 45

Gregory R. Jackson, Christine A. Curcio, Kenneth R. Sloan,
Cynthia Owsley

3.1	Introduction to Age-Related Maculopathy	45
3.2	Photoreceptor Loss	47
3.3	Photoreceptor Dysfunction	51
3.3.1	Topography of Loss and Dysfunction	52
3.4	Photoreceptor Function as a Bioassay of RPE and Bruch’s Membrane Health	54
3.5	Impairment of Transport Between RPE and Photoreceptors	56
3.6	Summary	57
	References	58

4 Genes and Age-Related Macular Degeneration 63

Robyn H. Guymer, Niro Narendran, Paul N. Baird

4.1	Age-Related Macular Degeneration, a Complex Genetic Disease	63
4.2	Genetic Basis of Disease	64
4.2.1	Family Studies	64
4.2.2	Sibling Studies	64
4.2.3	Twin Studies	65
4.3	Approaches to Genetic Investigation of AMD	65
4.3.1	Linkage Analysis	65
4.3.2	Candidate-Gene Screening	67

4.4	Future Directions	73
4.4.1	Single-Nucleotide Polymorphisms	73
4.4.2	Microarrays	73
4.4.3	Proteomics	74
4.5	Conclusions	74
	References	75
5	Epidemiology of Age-Related Macular Degeneration	79
	Ronald Klein	
5.1	Prevalence and Incidence of Age-Related Macular Degeneration	79
5.1.1	Introduction	79
5.1.2	Prevalence of Age-Related Macular Degeneration	80
5.1.3	Prevalence: Race/Ethnicity	81
5.1.4	Incidence of Age-Related Macular Degeneration	82
5.2	Risk Factors for Age-Related Macular Degeneration	82
5.2.1	Introduction	82
5.2.2	Familial Factors	83
5.2.3	Systemic Factors	83
5.2.4	Lifestyle Behavior	87
5.2.5	Environmental Factors	89
5.2.6	Ocular Factors	90
5.2.7	Socioeconomic Factors and Work Exposures	92
5.3	Age-Related Macular Degeneration and Survival	93
5.4	Public Health Issues	93
5.5	Conclusions	93
	References	94
6	Prevalence and Risk Factors for Age-Related Macular Degeneration in China	103
	Zheng Qin Yin, Meidong Zhu, Wen Shan Jiang	
6.1	Introduction	103
6.2	Regional Prevalence and Relationship of Morbidity to Age and Gender	104
6.2.1	Population-Based Studies	105
6.2.2	Clinical Review Studies	106
6.2.3	The Relationship of Morbidity to Age and Gender	107
6.3	Prevalence of ‘Wet’ and ‘Dry’ AMD	107
6.4	Visual Acuity in AMD	107

- 6.5 Risk Factors of AMD in China 107
 - 6.5.1 Race/Ethnicity 109
 - 6.5.2 Light Exposures/Occupation 109
 - 6.5.3 Smoking 109
 - 6.5.4 Drinking 110
 - 6.5.5 Systemic Diseases 111
- 6.6 Conclusions 111
- References 111

- 7 Experimental Models of Macular Degeneration 113
 - Ray F. Gariano

 - 7.1 Introduction 113
 - 7.2 Aging 113
 - 7.3 Laser-Induced CNV 114
 - 7.4 Growth Factor-Induced CNV 114
 - 7.5 Genetically Defined Animal Models 116
 - 7.6 Conclusions 118
 - References 118

- 8 Transporters and Oxidative Stress in AMD 123
 - David V. Pow, Robert K.P. Sullivan, Susan M. Williams,
Elizabeth WoldeMussie

 - 8.1 Redox Reactions, Health, Oxidative Damage and Disease 123
 - 8.2 Does Epidemiology Support a Role for Oxidation in AMD? 124
 - 8.3 Exogenous Factors Influencing AMD Incidence 125
 - 8.4 Hallmark Features of Oxidative Damage and Free Radical Damage . . 125
 - 8.4.1 Oxidized Proteins 125
 - 8.4.2 Oxidized Lipids 125
 - 8.4.3 DNA Damage 125
 - 8.5 Oxidative Challenges in the Eye 125
 - 8.5.1 Endogenous Antioxidants, Enzymes and Related Molecules
in the Retina 126
 - 8.5.2 Classes of Antioxidants 128
 - 8.5.3 The Glutathione System 128
 - 8.5.4 GSH in the Retina: Intrinsic Synthesis and Possible Interplay
with the RPE 128
 - 8.5.5 Synthesis of GSH 128

8.5.6	The GSH-GSSG Cycle	129
8.5.7	Elimination of Superoxides by Superoxide Dismutases	131
8.5.8	Ascorbic Acid	132
8.5.9	Vitamin E	132
8.5.10	Taurine	133
8.5.11	Metallothionein	136
8.5.12	Zinc, Copper, Selenium and Manganese	136
8.5.13	Selenium Compounds	137
8.5.14	Manganese	137
8.5.15	Macular Pigments	138
8.5.16	Ascorbate and Recycling of Carotenoids	138
8.5.17	A Summary of Mechanisms for Antioxidant Protection	138
8.6	Cellular Interactions and Photoreceptor Death	138
8.6.1	Light-Mediated Damage: Experimental Lesions and AMD	139
8.6.2	Mechanisms of Cell Death	140
8.6.3	Cell Death in Response to Oxidative Damage	140
8.7	A Role for Glial cells in AMD?	141
8.7.1	Metabolic Functions of Müller Cells in the AMD Retina	141
8.7.2	Cell Death and Glutamate Toxicity	144
8.8	Conclusions	144
	References	145
9	Photoreceptor Stability and Degeneration in Mammalian Retina: Lessons from the Edge	149
	Jonathan Stone, Kyle Mervin, Natalie Walsh, Krisztina Valter, Jan M. Provis, Philip L. Penfold	
9.1	Introduction	149
9.2	Approach	150
9.3	Stages in Photoreceptor Degeneration at the Edge of the Retina	150
9.3.1	Postnatal Development of the Edge: Site of Early Stress and Degeneration	150
9.3.2	The Edge of the Retina Is Functionally Degraded	154
9.3.3	The Edge of the Retina Is Highly Stable in the Face of Acute Stress	155
9.3.4	The Adult Retina Aged 2 Years: Observations in the Marmoset	155
9.3.5	The Adult Retina Aged 20 Years: Observations in the Baboon	155
9.3.6	The Adult Retina Aged 30–70 Years: Observations in the Human	158
9.3.7	Evidence of Progression in Edge Degeneration in Humans	161
9.4	Discussion	161
9.4.1	The Edge of the Retina as a Model of Retinal Degeneration	162
9.4.2	Why Is the Protection of Photoreceptors Stress-Inducible?	162

9.4.3 Vulnerability to Oxidative Stress in Mice and Humans 163

9.4.4 The Link to AMD 163

References 164

**10 Clinical Strategies for Diagnosis and Treatment of AMD:
Implications from Research 167**

Scott W. Cousins, Karl G. Csaky, Diego G. Espinosa-Heidmann

10.1 Dry AMD 167

10.1.1 Definition of Dry AMD 167

10.1.2 Pathogenic Mechanisms for Drusen Formation 168

10.1.3 Established or Evaluated Treatments 170

10.1.4 Ongoing Trials: Multicenter Investigation of Rheopheresis
for AMD (MIRA-1) Study Group 172

10.1.5 Future Research 172

10.2 Wet AMD 178

10.2.1 Definition of Neovascular AMD 178

10.2.2 Pathogenic Mechanisms for CNV Formation 180

10.2.3 Established or Evaluated Treatments for Neovascular AMD 184

10.2.4 Therapies Currently in Clinical Trial 185

10.2.5 Future Research 189

References 191

Subject Index 201

List of Contributors

Chapter 1

Anita Hendrickson

Department of Biological Structure, University of Washington,
1959 NE Pacific Street, Box 357420, Seattle, WA 98195-7420, USA

Department of Ophthalmology, University of Washington, 1959 NE Pacific Street,
Box 357420, Seattle, WA 98195-7420, USA
e-mail: anitah@u.washington.edu, Tel.: +1-206-6852273, Fax: +1-206-5431524

Chapter 2

Philip L. Penfold, James Wong, Diana van Driel, Jan M. Provis, Michele C. Madigan

Save Sight Institute, University of Sydney, GPO 4337 Sydney 2001, NSW, Australia

Jan M. Provis

Department of Anatomy and Histology, University of Sydney 2006, NSW, Australia

Current address: Philip L. Penfold, Jan M. Provis, Research School of Biological
Sciences, The Australian National University, GPO Box 475, Canberra, ACT 2601,
ACT, Australia

e-mail: philip.penfold@regenera.com.au, Tel.: +61-2-62574155, Fax: +61-2-62574355

e-mail: jan.provis@anu.edu.au, Tel.: +61-2-61254242, Fax: +61-2-61250758

Chapter 3

Gregory R. Jackson, Christine A. Curcio, Cynthia Owsley

Department of Ophthalmology, University of Alabama School of Medicine,
Birmingham, AL 35294-0009, USA

e-mail: jackson@uab.edu, Tel.: +1-205-325-8674, Fax: +1-205-325-8692

Kenneth R. Sloan

Department of Computer and Information Sciences, University of Alabama at
Birmingham, AL, USA

Chapter 4

Robyn H. Guymer, Paul N. Baird

Department of Ophthalmology, University of Melbourne, 1st Floor Royal Victorian Eye and Ear Hospital, 32 Gisborne Street. East Melbourne 3002
e-mail: rhg@unimelb.edu.au, Tel.: +613 9929-8360, Fax: +613-9662-3859

Robyn H. Guymer, Niro Narendran, Paul N. Baird

Centre For Eye Research Australia, University of Melbourne,
1st Floor Royal Victorian Eye and Ear Hospital, 32 Gisborne Street,
East Melbourne 3002, Australia

Chapter 5

Ronald Klein

Department of Ophthalmology and Visual Sciences,
University of Wisconsin Medical School, Madison, WI, USA
e-mail: kleinr@epi.ophth.wisc.edu, Tel.: +1-608-263-0280, Fax: +1-608-263-0279

Chapter 6

Zheng Qin Yin, Meidong Zhu, Wen Shan Jiang

Southwest Eye Hospital, Southwest Hospital, Third Military Medical University,
40038, Chongqing, Peoples Republic of China

Meidong Zhu

Save Sight Institute, University of Sydney, NSW 2006, Sydney, Australia
e-mail: zqyin@mail.tmmu.com.cn, Tel.: +86-23-6875-4401, Fax: +86-23-6875-3686

Chapter 7

Ray F. Gariano

Department of Ophthalmology, Stanford University School of Medicine
330 Pasteur Dr., Palo Alto, CA 94305, USA

Santa Clara Valley Medical Center, Santa Clara, CA, USA
e-mail: Ray.Gariano@hhs.co.santa-clara.ca.us, Tel.: +1-408-885-6775,
Fax: +1-408-885-7166

Chapter 8

David V. Pow, Robert K.P. Sullivan, Susan M. Williams

School of Biomedical Sciences, University of Queensland, Australia
e-mail: d.pow@mailbox.uq.edu.au, Tel.: +7-33654086, Fax: +7-33651766

Elizabeth WoldeMussie

Department of Biological Sciences, Allergan Inc., Irvine, CA, USA

Chapter 9**Jonathan Stone, Krisztina Valter, Jan Provis, Philip Penfold**

Biological Sciences, Australian National University, Canberra, Australia
e-mail: stone@rsbs.anu.edu.au, Tel.: +61-26125-3841, Fax: +61-26125-0758

Jonathan Stone, Kyle Mervin, Natalie Walsh, Krisztina Valter, Jan Provis

Department of Anatomy and Histology and Institute for Biomedical Research,
University of Sydney, Australia

Jan Provis, Philip Penfold

Save Sight Institute, Department of Clinical Ophthalmology, University of Sydney

Chapter 10**Scott W. Cousins, Diego G. Espinosa-Heidmann**

Department of Ophthalmology, Bascom Palmer Eye Institute,
University of Miami School of Medicine, Miami, FL, USA

Karl G. Csaky

National Eye Institute, National Institutes of Health, Bethesda, MD, USA
e-mail: scousins@med.miami.edu, despinosa@med.miami.edu,
Tel.: +1-305-326-6329, Fax: +1-305-326-6536

<http://www.springer.com/978-3-540-20058-1>

Macular Degeneration

Penfold, P.L.; Provis, J.M. (Eds.)

2005, XVIII, 202 p. 200 illus., 100 illus. in color.,

Hardcover

ISBN: 978-3-540-20058-1